186 related articles for article (PubMed ID: 16437218)
1. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
3. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
4. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET.
Dimitrakopoulou-Strauss A; Georgoulias V; Eisenhut M; Herth F; Koukouraki S; Mäcke HR; Haberkorn U; Strauss LG
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):823-30. PubMed ID: 16570185
[TBL] [Abstract][Full Text] [Related]
6. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
[TBL] [Abstract][Full Text] [Related]
7. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
[TBL] [Abstract][Full Text] [Related]
8. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
Al-Ibraheem A; Bundschuh RA; Notni J; Buck A; Winter A; Wester HJ; Schwaiger M; Scheidhauer K
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
[TBL] [Abstract][Full Text] [Related]
10. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
12. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.
Malmberg C; Ripa RS; Johnbeck CB; Knigge U; Langer SW; Mortensen J; Oturai P; Loft A; Hag AM; Kjær A
J Nucl Med; 2015 Dec; 56(12):1895-900. PubMed ID: 26429961
[TBL] [Abstract][Full Text] [Related]
13. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
15. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
16. Intraarterial treatment of GEP NET: (68)Ga-DOTATOC SUV cannot predict (90)Y-DOTATOC uptake.
Brogsitter C; Faulhaber D; Kotzerke J
Clin Cancer Res; 2011 Apr; 17(7):2065. PubMed ID: 21447724
[No Abstract] [Full Text] [Related]
17. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
19. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.
Kratochwil C; Mavriopoulou E; Rath D; Afshar-Oromieh A; Apostolopoulos D; Haufe S; Mier W; Haberkorn U; Giesel FL
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):116-20. PubMed ID: 24382404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
